236 related articles for article (PubMed ID: 23494221)
1. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
[TBL] [Abstract][Full Text] [Related]
2. DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions.
Sun Y; Li S; Shen K; Ye S; Cao D; Yang J
Int J Clin Exp Pathol; 2015; 8(11):14939-45. PubMed ID: 26823825
[TBL] [Abstract][Full Text] [Related]
3. [Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].
Zhong ZJ; Yang JX; Cao DY; Sun Y; Sun LL; Cheng XM; Chen J; Lang JH; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):196-200. PubMed ID: 22781071
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients.
Pierini S; Jordanov SH; Mitkova AV; Chalakov IJ; Melnicharov MB; Kunev KV; Mitev VI; Kaneva RP; Goranova TE
Head Neck; 2014 Aug; 36(8):1103-8. PubMed ID: 23804521
[TBL] [Abstract][Full Text] [Related]
5. Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.
Bhatia V; Goel MM; Makker A; Tewari S; Yadu A; Shilpi P; Kumar S; Agarwal SP; Goel SK
Biomed Res Int; 2014; 2014():248419. PubMed ID: 24991542
[TBL] [Abstract][Full Text] [Related]
6. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
Iliopoulos D; Oikonomou P; Messinis I; Tsezou A
Oncol Rep; 2009 Jul; 22(1):199-204. PubMed ID: 19513524
[TBL] [Abstract][Full Text] [Related]
7. Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population.
Sinha R; Hussain S; Mehrotra R; Kumar RS; Kumar K; Pande P; Doval DC; Basir SF; Bharadwaj M
PLoS One; 2013; 8(4):e60142. PubMed ID: 23573237
[TBL] [Abstract][Full Text] [Related]
8. Population-based case-control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology.
Sun LL; Cao DY; Yang JX; Li H; Zhou XR; Song ZQ; Cheng XM; Chen J; Shen K
Arch Gynecol Obstet; 2012 May; 285(5):1433-9. PubMed ID: 22116316
[TBL] [Abstract][Full Text] [Related]
9. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
[TBL] [Abstract][Full Text] [Related]
10. Limited Role of Promoter Methylation of
Sun LL; Liu Y; Sun X; Pan L; Wu D; Wang YD
Chin Med J (Engl); 2018 Apr; 131(8):939-944. PubMed ID: 29664054
[TBL] [Abstract][Full Text] [Related]
11. The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.
Cecener G; Tunca B; Egeli U; Bekar A; Tezcan G; Erturk E; Bayram N; Tolunay S
Cell Mol Neurobiol; 2012 Mar; 32(2):237-44. PubMed ID: 21928112
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
Shi HR; Wu QH; Suo ZH; Nesland JM
Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
[TBL] [Abstract][Full Text] [Related]
13. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.
Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E
Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212
[TBL] [Abstract][Full Text] [Related]
14. Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
Huang J; Luo JY; Tan HZ
PLoS One; 2019; 14(10):e0222772. PubMed ID: 31574102
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Psofaki V; Kalogera C; Tzambouras N; Stephanou D; Tsianos E; Seferiadis K; Kolios G
World J Gastroenterol; 2010 Jul; 16(28):3553-60. PubMed ID: 20653064
[TBL] [Abstract][Full Text] [Related]
16. The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis.
Shu R; He J; Wu C; Gao J
Tumour Biol; 2017 Jun; 39(6):1010428317709126. PubMed ID: 28639889
[TBL] [Abstract][Full Text] [Related]
17. Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia.
Wijetunga NA; Belbin TJ; Burk RD; Whitney K; Abadi M; Greally JM; Einstein MH; Schlecht NF
Gynecol Oncol; 2016 Sep; 142(3):566-73. PubMed ID: 27401842
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
[TBL] [Abstract][Full Text] [Related]
19. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.
Neyaz MK; Kumar RS; Hussain S; Naqvi SH; Kohaar I; Thakur N; Kashyap V; Das BC; Husain SA; Bharadwaj M
Biomarkers; 2008 Sep; 13(6):597-606. PubMed ID: 18608185
[TBL] [Abstract][Full Text] [Related]
20. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer.
Pehlivan S; Artac M; Sever T; Bozcuk H; Kilincarslan C; Pehlivan M
Cancer Genet Cytogenet; 2010 Sep; 201(2):128-32. PubMed ID: 20682398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
